{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:24:04Z","timestamp":1787167444913,"version":"build-2736575974"},"reference-count":110,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Child and Adolescent Psychopharmacology"],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>\n                      Methylphenidate (MPH) is efficacious in reducing symptoms of attention-deficit\/hyperactivity disorder (ADHD), but there are no data about the efficacy and safety of its new formulation (ORADUR\n                      <jats:sup>\u00ae<\/jats:sup>\n                      -MPH extended release, ORADUR-MPH) in patients with ADHD, which is the study objective.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method:<\/jats:title>\n                    <jats:p>This was a Phase III, multicenter, randomized, double-blind, placebo-controlled, two-way crossover clinical trial. One hundred children and adolescents with a clinical diagnosis of ADHD (72.7% male) received at least one dose of ORADUR-MPH or a placebo during the 2-week treatment period of each phase. The primary efficacy measure was the Swanson, Nolan, and Pelham-IV-teacher (SNAP-IV-T) form. Secondary efficacy measures included the SNAP-IV-parent form, the Clinical Global Impression: ADHD-Severity score, the Conner's Teacher's Rating Scale score, and the investigator's rating for 18 Diagnostic and Statistical Manual of Mental Disorders, 5th edition ADHD symptoms. In addition, data related to vital signs, body weight, physical examination, laboratory testing, and adverse events (AEs) were also collected. All data were analyzed on an intent-to-treat basis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Without adjusting for differences in demographics and baseline measures, both treatment groups showed significant reductions in ADHD and oppositional defiant disorder symptoms after a 2-week treatment with greater effect sizes (Cohen's\n                      <jats:italic toggle=\"yes\">d<\/jats:italic>\n                      ) in the ORADUR-MPH group (Cohen's\n                      <jats:italic toggle=\"yes\">d<\/jats:italic>\n                      ranging from \u22120.41 to \u22121.64; placebo, Cohen's\n                      <jats:italic toggle=\"yes\">d<\/jats:italic>\n                      ranging from \u22120.26 to \u22121.18), except for oppositional symptoms, regardless of the informants. For the primary efficacy measure, ORADUR-MPH was significantly superior to the placebo, as evidenced by lower values for and greater reductions in the SNAP-IV-T scores at the endpoint (Cohen's\n                      <jats:italic toggle=\"yes\">d<\/jats:italic>\n                      \u2009=\u2009\u22120.16,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.005) and from baseline to the endpoint (Cohen's\n                      <jats:italic toggle=\"yes\">d<\/jats:italic>\n                      \u2009=\u2009\u22120.19,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.006), respectively. There were no serious AEs during the clinical study period. The most frequently observed AE was decreased appetite (49.1%). Most physical and laboratory test variables remained within the normal range.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>\n                      Once-daily ORADUR-MPH is an effective, well-tolerable, and safe treatment for children and adolescents with ADHD.\n                      <jats:uri xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/ClinicalTrials.gov\">ClinicalTrials.gov<\/jats:uri>\n                      number, NCT02450890.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/cap.2020.0104","type":"journal-article","created":{"date-parts":[[2021,1,4]],"date-time":"2021-01-04T16:49:50Z","timestamp":1609778990000},"page":"164-178","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":14,"title":["A Randomized, Double-Blind, Placebo-Controlled, Two-Way Crossover Clinical Trial of ORADUR-Methylphenidate for Treating Children and Adolescents with Attention-Deficit\/Hyperactivity Disorder"],"prefix":"10.1177","volume":"31","author":[{"given":"Yu-Shu","family":"Huang","sequence":"first","affiliation":[{"name":"Department of Child Psychiatry, Chang Gung Memorial Hospital and University, Taoyuan, Taiwan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chin-Bin","family":"Yeh","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Tri-Service General Hospital and University, Taipei, Taiwan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chin-Hung","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Chang Gung Memorial Hospital and University, Chiayi, Taiwan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Yung","family":"Shang","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, National Taiwan University Hospital and College of Medicine, National Taiwan University, Taipei, Taiwan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan Shur-Fen","family":"Gau","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, National Taiwan University Hospital and College of Medicine, National Taiwan University, Taipei, Taiwan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2021,4,16]]},"reference":[{"key":"e_1_3_5_2_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.chi.0000128791.10014.ac"},{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/ar.21403"},{"key":"e_1_3_5_4_1","unstructured":"American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders 4th ed. Washington DC: American Psychiatric Association; 1994."},{"key":"e_1_3_5_5_1","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders 5th ed. Washington DC: American Psychiatric Association; 2013.","DOI":"10.1176\/appi.books.9780890425596"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2008.0146"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/jcpp.12272"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpsycho.2005.03.008"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.5453"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ridd.2014.12.025"},{"key":"e_1_3_5_11_1","first-page":"1","article-title":"Prevalence of DSM-5 mental disorders in a nationally representative sample of children in Taiwan: Methodology and main findings","volume":"30","author":"Chen YL","year":"2019","unstructured":"Chen YL, , Chen WJ, , Lin KC, , Shen LJ, , Gau SS: Prevalence of DSM-5 mental disorders in a nationally representative sample of children in Taiwan: Methodology and main findings. Epidemiol Psychiatr Sci, 30:1\u20139, 2019.","journal-title":"Epidemiol Psychiatr Sci"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfma.2017.06.013"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1503\/jpn.140106"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291715002767"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/jcpp.12450"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2869.2010.00832.x"},{"key":"e_1_3_5_17_1","first-page":"1","article-title":"White matter endophenotype candidates for ADHD: A diffusion imaging tractography study with sibling design","volume":"22","author":"Chiang HL","year":"2019","unstructured":"Chiang HL, , Hsu YC, , Shang CY, , Tseng WI, , Gau SS: White matter endophenotype candidates for ADHD: A diffusion imaging tractography study with sibling design. Psychol Med, 22:1\u201311, 2019.","journal-title":"Psychol Med"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2017.1317344"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2016.0002"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2015.08.024"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2011.0006"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1819.2009.01937.x"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2017.1389894"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-13-237"},{"key":"e_1_3_5_25_1","doi-asserted-by":"crossref","unstructured":"Conners CK : Conners' Rating Scales-Revised Technical Manual. North Tonawanda (New York) Multi-Health Systems 1997.","DOI":"10.1037\/t81067-000"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1177\/070674370200601S04"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1022606501530"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(18)30269-4"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-017-0409-0"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2011.02.036"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-018-0269-7"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.adolescence.2016.10.013"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2018.02.001"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2015.20"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.4103\/2229-516X.157162"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2869.2006.00552.x"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1080\/j.1440-1614.1999.00610.x"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v69n0118"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.162.7.1344"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2006.0091"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1093\/jpepsy\/jsn133"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.3109\/00048670903282733"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145709990836"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1002\/mpr.237"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2006.16.286"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2006.16.441"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1177\/1087054705284241"},{"key":"e_1_3_5_48_1","author":"Goldman LS","unstructured":"Goldman LS, , Genel M, , Bezman RJ, , Slanetz PJ. Diagnosis and treatment of attention-deficit\/hyperactivity disorder in children and adolescents. Council on Scientific Affairs, American Medical Association. JAMA 279:1100\u20131107, 1998.","journal-title":"JAMA"},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0000000000000231"},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200721010-00004"},{"key":"e_1_3_5_51_1","author":"Hearne LJ","unstructured":"Hearne LJ, , Lin HY, , Sanz-Leon P, , Tseng WI, , Gau SS, , Roberts JA, , Cocchi L. ADHD symptoms map onto noise-driven structure-function decoupling between hub and peripheral brain regions. Mol Psychiatry 31:019\u20130554, 2019.","journal-title":"Mol Psychiatry"},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0178187"},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.2174\/138161211796197179"},{"key":"e_1_3_5_54_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0127157"},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10802-011-9556-9"},{"key":"e_1_3_5_56_1","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2014.240"},{"key":"e_1_3_5_57_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10803-017-3125-1"},{"key":"e_1_3_5_58_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00787-018-1106-3"},{"key":"e_1_3_5_59_1","doi-asserted-by":"publisher","DOI":"10.1186\/1744-9081-5-12"},{"key":"e_1_3_5_60_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-026478"},{"key":"e_1_3_5_61_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyg.2013.00863"},{"key":"e_1_3_5_62_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.4980"},{"key":"e_1_3_5_63_1","article-title":"Design, analysis, and reporting of crossover trials for inclusion in a meta-analysis","volume":"10","author":"Li T","year":"2015","unstructured":"Li T, , Yu T, , Hawkins BS, , Dickersin K: Design, analysis, and reporting of crossover trials for inclusion in a meta-analysis. PLoS One, 10:e0133023, 2015.","journal-title":"PLoS One"},{"key":"e_1_3_5_64_1","doi-asserted-by":"publisher","unstructured":"Lin HY Kessler BS Tseng WI Gau SS : Increased functional segregation related to the salience network in unaffected siblings of youths with ADHD. J Am Acad Child Adolesc Psychiatry 2020 [Epub haead of print]; DOI: 10.1016\/j.jaac.2019.11.012.","DOI":"10.1016\/j.jaac.2019.11.012"},{"key":"e_1_3_5_65_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291718001599"},{"key":"e_1_3_5_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ridd.2015.07.026"},{"key":"e_1_3_5_67_1","doi-asserted-by":"publisher","DOI":"10.1177\/0004867415609423"},{"key":"e_1_3_5_68_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200262150-00012"},{"key":"e_1_3_5_69_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.2013.786041"},{"key":"e_1_3_5_70_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2006.16.687"},{"key":"e_1_3_5_71_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2008.0148"},{"key":"e_1_3_5_72_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000000747"},{"key":"e_1_3_5_73_1","doi-asserted-by":"publisher","DOI":"10.1186\/1745-6215-10-27"},{"key":"e_1_3_5_74_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2007.0015"},{"key":"e_1_3_5_75_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737175.2019.1628640"},{"key":"e_1_3_5_76_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881116632377"},{"key":"e_1_3_5_77_1","doi-asserted-by":"publisher","DOI":"10.1177\/1087054713476549"},{"key":"e_1_3_5_78_1","author":"Ni HC","unstructured":"Ni HC, , Shang CY, , Gau SS, , Lin YJ, , Huang HC, , Yang LK. A head-to-head randomized clinical trial of methylphenidate and atomoxetine treatment for executive function in adults with attention-deficit hyperactivity disorder. Int J Neuropsychopharmacol 16:1959\u20131973, 2013.","journal-title":"Int J Neuropsychopharmacol"},{"key":"e_1_3_5_79_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2018.0068"},{"key":"e_1_3_5_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2012.03.028"},{"key":"e_1_3_5_81_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.107.6.e105"},{"key":"e_1_3_5_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2018.05.012"},{"key":"e_1_3_5_83_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2017.0084"},{"key":"e_1_3_5_84_1","unstructured":"QPS T: A Phase I Five-Way Crossover Study to Compare the Pharmacokinetics of Test Methylphenidate Products (ORADUR\u00ae-Methylphenidate Capsules 44\u2009mg) to a Commercial Methylphenidate Product (Concerta\u00ae Extended Release Tablets 36\u2009mg) After a Single Oral Administration in Healthy Adult Volunteers Under Fed Conditions. Orient Pharma Co. Ltd. Taipei Taiwan 2013."},{"key":"e_1_3_5_85_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12402-015-0176-z"},{"key":"e_1_3_5_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-1211(01)00214-5"},{"key":"e_1_3_5_87_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.2005.25.7.909"},{"key":"e_1_3_5_88_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(17)30167-0"},{"key":"e_1_3_5_89_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-0348-8171-5_4"},{"key":"e_1_3_5_90_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-019-0545-7"},{"key":"e_1_3_5_91_1","first-page":"1","article-title":"Effects of the dopamine transporter gene on striatal functional connectivity in youths with attention-deficit\/hyperactivity disorder","volume":"7","author":"Shang CY","year":"2020","unstructured":"Shang CY, , Lin HY, , Gau SS: Effects of the dopamine transporter gene on striatal functional connectivity in youths with attention-deficit\/hyperactivity disorder. Psychol Med, 7:1\u201311, 2020a.","journal-title":"Psychol Med"},{"key":"e_1_3_5_92_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2015.0035"},{"key":"e_1_3_5_93_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11682-017-9749-0"},{"key":"e_1_3_5_94_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2019.0139"},{"key":"e_1_3_5_95_1","first-page":"1","article-title":"Differential effects of methylphenidate and atomoxetine on intrinsic brain activity in children with attention deficit hyperactivity disorder","volume":"30","author":"Shang CY","year":"2016","unstructured":"Shang CY, , Yan CG, , Lin HY, , Tseng WY, , Castellanos FX, , Gau SS: Differential effects of methylphenidate and atomoxetine on intrinsic brain activity in children with attention deficit hyperactivity disorder. Psychol Med, 30:1\u201313, 2016.","journal-title":"Psychol Med"},{"key":"e_1_3_5_96_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2018.0076"},{"key":"e_1_3_5_97_1","first-page":"e50","article-title":"A randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in attention deficit-hyperactivity disorder","volume":"13","author":"Steele M","year":"2006","unstructured":"Steele M, , Weiss M, , Swanson J, , Wang J, , Prinzo RS, , Binder CE: A randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in attention deficit-hyperactivity disorder. Can J Clin Pharmacol, 13:e50\u2013e62, 2006.","journal-title":"Can J Clin Pharmacol"},{"key":"e_1_3_5_98_1","article-title":"Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents\u2014assessment of adverse events in non-randomised studies","volume":"5","author":"Storebo OJ","year":"2018","unstructured":"Storebo OJ, , Pedersen N, , Ramstad E, , Kielsholm ML, , Nielsen SS, , Krogh HB, , Moreira-Maia CR, , Magnusson FL, , Holmskov M, , Gerner T, , Skoog M, , Rosendal S, , Groth C, , Gillies D, , Buch Rasmussen K, , Gauci D, , Zwi M, , Kirubakaran R, , Hakonsen SJ, , Aagaard L, , Simonsen E, , Gluud C: Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents\u2014assessment of adverse events in non-randomised studies. Cochrane Database Syst Rev, 5:CD012069, 2018.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_5_99_1","author":"Storebo OJ","unstructured":"Storebo OJ, , Ramstad E, , Krogh HB, , Nilausen TD, , Skoog M, , Holmskov M, , Rosendal S, , Groth C, , Magnusson FL, , Moreira-Maia CR, , Gillies D, , Buch Rasmussen K, , Gauci D, , Zwi M, , Kirubakaran R, , Forsbol B, , Simonsen E, , Gluud C: Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Cochrane Database Syst Rev CD009885, 2015.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_5_100_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.7850"},{"key":"e_1_3_5_101_1","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S164807"},{"key":"e_1_3_5_102_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-200102000-00011"},{"key":"e_1_3_5_103_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0166-4328(01)00433-8"},{"key":"e_1_3_5_104_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.113.3.e206"},{"key":"e_1_3_5_105_1","doi-asserted-by":"publisher","DOI":"10.1590\/S0100-879X2008005000011"},{"key":"e_1_3_5_106_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13034-017-0165-4"},{"key":"e_1_3_5_107_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10578-010-0204-3"},{"key":"e_1_3_5_108_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-006-0318-2"},{"key":"e_1_3_5_109_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpr.2007.10.007"},{"key":"e_1_3_5_110_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2016.0177"},{"key":"e_1_3_5_111_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2019-0811"}],"container-title":["Journal of Child and Adolescent Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/cap.2020.0104","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cap.2020.0104","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cap.2020.0104","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:56:01Z","timestamp":1777388161000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/cap.2020.0104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":110,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["10.1089\/cap.2020.0104"],"URL":"https:\/\/doi.org\/10.1089\/cap.2020.0104","relation":{},"ISSN":["1044-5463","1557-8992"],"issn-type":[{"value":"1044-5463","type":"print"},{"value":"1557-8992","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4]]}}}